New Medical Data Links Diabetes and Weight-Loss Medications to Reduced Liver Failure and Mortality in Older Adults
Older adults taking diabetes and weight-loss medications experience a 28 percent lower risk of liver failure and a 45 percent reduction in all-cause mortality, according to medical research published in the journal Age and Ageing. The study analyzed health data from approximately 88,000 patients with a mean age of 72 who suffer from metabolic dysfunction-associated steatotic liver disease.
Participants in the study were divided evenly between those using these medications and those who did not use them. Beyond the drop in liver failure and mortality, the research also identified a general decline in hospital admissions among patients maintaining regular treatment, which helps ease pressure on healthcare systems.
Cardiovascular and Kidney Protections Observed Across Patient Groups
Research published in The Lancet shows that semaglutide, the active ingredient in Ozempic and Wegovy, helps lower the risk of heart attacks, strokes, and cardiovascular-related deaths in overweight or obese individuals with pre-existing heart disease. These cardiovascular benefits appeared across various body weight categories, indicating that some effects operate independently of total weight loss.
Additional clinical findings from the FLOW trial published in the New England Journal of Medicine demonstrate that semaglutide reduces major kidney-related complications and cardiovascular death by 24 percent in patients with type 2 diabetes and chronic kidney disease. Researchers attribute these outcomes to improved blood sugar control, better blood pressure regulation, and reduced inflammation.
Joint Mobility and Liver Inflammation Improvements
Clinical trials indicate that GLP-1 medications alleviate knee osteoarthritis pain and improve mobility in obese adults, though researchers continue to study whether these changes stem strictly from weight loss or other internal drug mechanisms. In studies focusing on metabolic dysfunction-associated steatohepatitis, abbreviated as MASH, 62.9 percent of participants receiving semaglutide achieved resolution of steatohepatitis without worsening liver fibrosis, compared to 34.3 percent in the placebo group.
Real-world studies presented at the European Respiratory Society congress linked GLP-1 use to reduced flare-ups in respiratory conditions, including asthma and chronic obstructive pulmonary disease. These treatments simulate the glucagon-like peptide-1 hormone to slow digestion and suppress appetite, which requires specialized clinical supervision to sustain weight management results.
Potential Adverse Effects and Unresolved Risks
Despite the clinical benefits for the liver and heart, researchers identified potential negative side effects associated with the medications. Patients taking these drugs showed higher diagnoses of conditions such as osteoporosis and retinopathy, an eye disease affecting the retina.
Furthermore, the data showed no significant reduction in the risk of heart attacks and strokes within the specific older adult cohort evaluated in the Age and Ageing study, contrasting with broader cardiovascular trials. Common adverse reactions include vomiting, requiring close medical oversight as physicians work to balance clinical gains against newly documented risks.
Frequently Asked Questions About GLP-1 Medications and Older Adults
What specific liver condition did the study examine in older patients?
The research evaluated metabolic dysfunction-associated steatotic liver disease among roughly 88,000 patients with an average age of 72.
How do GLP-1 receptor agonists affect the body’s digestive process?
These drugs mimic the glucagon-like peptide-1 hormone to regulate hunger and satiety, which naturally slows digestion and reduces appetite.
What specific kidney trial evaluated semaglutide for patients with type 2 diabetes?
The FLOW clinical trial, published in the New England Journal of Medicine, tracked patients with type 2 diabetes and chronic kidney disease to measure major renal and cardiovascular outcomes.